A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs CC 92480 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Celgene Corporation
- 09 Mar 2018 Planned End Date changed from 1 Jun 2022 to 1 Mar 2020.
- 09 Mar 2018 Planned primary completion date changed from 1 Jun 2022 to 1 Jan 2020.
- 02 Mar 2018 Planned number of patients changed from 120 to 160.